3-(3-chloro-4-isopropoxyphenyl)-5-(1-methyl-1H-pyrazol-5-yl)-1,2,4-oxadiazole | 1035214-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(3-chloro-4-isopropoxyphenyl)-5-(1-methyl-1H-pyrazol-5-yl)-1,2,4-oxadiazole
• 英文别名: 3-(3-Chloro-4-propan-2-yloxyphenyl)-5-(2-methylpyrazol-3-yl)-1,2,4-oxadiazole
• CAS: 1035214-70-0
• 化学式: C₁₅H₁₅ClN₄O₂
• 分子量: 318.763
• InChiKey: YQKOLFQVEDDDKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Novel therapeutic compounds
  申请人：Breinlinger Eric C.

  公开号：US20090069288A1

  公开（公告）日：2009-03-12

  Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.

  本文公开了公式（I）的新化合物，其中变量如本文所定义。公式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些疾病和病症，特别是炎症性疾病和疾病以及增生性疾病，如癌症。
• Novel oxadiazole compounds
  申请人：Hobson Adrian D.

  公开号：US20080280876A1

  公开（公告）日：2008-11-13

  Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.

  本发明揭示了新型噁二唑化合物、含有该化合物的药物组合物以及将这些化合物或组合物用作S1P家族G蛋白偶联受体的激动剂或拮抗剂，用于治疗与S1P家族受体活性调节相关的疾病，特别是通过提供有益的免疫抑制效应的疾病。
• US7834039B2
  申请人：——

  公开号：US7834039B2

  公开（公告）日：2010-11-16
• [EN] NOVEL OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'OXADIAZOLE INNOVANTS
  申请人：ABBOTT LAB

  公开号：WO2008076356A1

  公开（公告）日：2008-06-26

  [EN] Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.
  [FR] La présente invention concerne des composés d'oxadiazole innovants, des compositions pharmaceutiques contenant de tels composés et l'utilisation de ces composés ou compositions en tant qu'agonistes ou antagonistes de la famille S1P des récepteurs couplés à la protéine G dans le but de traiter des maladies associées à la modulation de l'activité des récepteurs de la famille S1P, en particulier en fournissant un effet immunosuppresseur efficace.
• [EN] NOVEL THERAPEUTIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS THÉRAPEUTIQUES
  申请人：ABBOTT LAB

  公开号：WO2009011850A2

  公开（公告）日：2009-01-22

  Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.